BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
Status:
RECRUITING
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
The goal of this research study is to test the efficacy of a novel immunosuppressive agent, belumosudil, in allogeneic hematopoietic stem cell transplant (HSCT) recipients who have been newly diagnosed or have developing (early stage) bronchiolitis obliterans syndrome (BOS).
The name of the study drugs involved in this study are:
* Belumosudil (an immunotherapy)
* Fluticasone (an intranasal corticosteroid)
* Azithromycin (an antibiotic)
* Montelukast (a leukotriene receptor antagonist)
* Prednisone (a corticosteroid)
Phase:
PHASE2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI) Sanofi